Recurrent Follicular Lymphoma: 619 Clinical Trials, Page 1 of 62

1 2 3 4 5 10 15 20  Last Page »

Hide Studies Not Open or Pending

10

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Condition(s):Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hairy Cell Leukemia; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Mucosa-Associated Lymphoid Tissue Lymphoma; Refractory Follicular Lymphoma; Refractory Hairy Cell Leukemia; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Small Lymphocytic LymphomaLast Updated:September 15, 2023Active, not recruiting

1 2 3 4 5 10 15 20  Last Page »

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.